Could levels of ANGPT2 predict clinical outcomes for patients with advanced melanoma?

Source: Bioanalysis Zone, April 2017

Investigators from the Dana-Farber Cancer Institute (Boston, MA, USA) have identified the serum-based protein angiopoietin-2 (ANGPT2) as a prognostic biomarker that could be utilized to predict clinical outcomes with patients with advanced melanoma and could identify those patients that might respond to immune checkpoint therapy.

Although immune checkpoint therapy has been proven as an effective treatment for a variety of different cancers, only some patients respond to these treatments. Therefore, the identification of the ANGPT2 protein is a significant step towards establishing why some patients respond to immune checkpoint therapy whilst others do not.

The team analyzed serum samples taken from patients with advanced melanoma who were undergoing immune checkpoint therapy from three clinical trials that had available survival data. The clinical trials were investigating different immune checkpoint inhibitors: ipilimumab; ipilimumab in combination with bevacizumab; and either nivolumab or pembrolizumab, which are both PD-1 inhibitors.

read the original full article

Melanoma Google Alerts

Melanoma Google Alerts is a summary of daily articles found in print and on the internet. The articles do not necessarily represent the views of Melbourne Melanoma Project

News Archives

News Categories